Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2012)

20 slides from Pharmacyclics's technical presentation, Jun 4, 2012

  1. Slide 1: Ibrutinib (PCI-32765) in Treatment Naive CLL Patients: Interim Results of a Phase Ib/II Study

    The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerablein Treatment Naive (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/Il Study JOHN C. BYRD, MD', RICHARD FURMAN, MD?, STEVEN COUTRE, MD3, JAN BURGER, MD, PHD4, KRISTIE BLUM,

  2. Slide 2: Bruton's Tyrosine Kinase (BTK)

    Bruton’s Tyrosine Kinase (BTK) A critical kinase for lymphoma cell survival and proliferation + BTKis expressed and functional across non-T-cell hematopoietic lineages + BTK functions downstream in a variety of receptors + Essential element of B-cell receptor signaling * Chemokine mediated migration

  3. Slide 3: Ibrutinib (PCI-32765), a selective inhibitor of BTK

    Ibrutinib (PCI-32765), a selective inhibitor of BTK Forms a specific bond with cysteine-481 in BTK Highly potent BTK inhibition at 1C50=0.5 nM * Orally administered with once daily dosing resulting in 24-hr target inhibition No cytotoxic effect on T-cells or NK-cells * InCLLcells promotes apoptosis

  4. Slide 4: PCYC-1102-CA: Phase IB/II in CLL/SLL

    PCYC-1102-CA: Phase IB/II in CLL/SLL PCYC-1102-CA Total enrollment 117 patients Dates enrolled 20% May 10 — 27% Jul 11 Relapsed/Refractory 420 mg/d (n=27) Median follow-up 17.5 months Treatment Naive 2 65 yrs 420 mg/d 6) Median follow-up 14.4 months Relapsed/Refractory 840 mg/d (n=34) Median follow-

  5. Slide 5: PCYC-1102-CA: Phase IB/II in CLL/SLL (Treatment naive population)

    PCYC-1102-CA: Phase IB/II in CLL/SLL (Treatment Naive 2 65 yrs population) Treatment Naive 2 65 yrs 420 mg/d (n=26) PCYC-1102-CA / Median follow-up 14.4 months 117 patients Dates enrolled 20! May 10 — 27 Jul 11 Treatment Naive 2 65 yrs 840 mg/d (n=5)* Median follow-up 7.4 months “The 840mg TN cohort

  6. Slide 6: Study Design

    Study Design: » Ibrutinib as a single agent for treatment naive CLL/SLL patients aged 65 and older » Two fixed continuous doses 420 mg/day or 840 mg/day until disease progression * Objectives to evaluate: — Safety — Response rate — PFS

  7. Slide 7: Patient Characteristics

    Patient Characteristics 420 mg/d (N=26) Age, years Median (Range): 71 (66 - 84) 71 (65-77) — 71(65-84) 270 years, # (%) 20(77) 3 (60) 23 (74) ECOG Performance Status, # (%) 0 18/25 (72) 2(40) 20/30 (67) 1 7/25 (28) 3 (60) 10/30 (33) B2 Microglobulin > 3mg/L 7 (27) C) 7 (23) Cytopenia at baseline, #

  8. Slide 8: PCYC-1102-CA: Patient Disposition

    PCYC-1102-CA: Patient Disposition (Treatment Naive 2 65 yrs) 420 mg/d 840 mg/d (N=26) ( Subjects Discontinued, # (%) 4 (15) 1 (20) Primary Reasons for Discontinuation, # (%) Disease Progression 14) 0(0) Adverse event 2(8)h« 1 (20)* Unrelated: viral syndrome Unrelated: Worsening GI hemorrhage Possibl

  9. Slide 9: Common AEs regardless of relationship

    Common AEs (> 20 %) regardless of relationship (Treatment Naive 2 65 yrs) Diarrhea Nausea Fatigue Dyspepsia Rash Contusion/Ecchymosis Dizziness Hypertension Vomiting 0% 10% 20% 30% 40% 50% 60% 70% MMM Grade1 @§§)Grade2 MM GradeS MM Grade 4

  10. Slide 10: Safety

    Safety (Treatment Naive 2 65 yrs) Total (N=31) Grade3 Grade 4 Grade 3/4 hematology toxicity, # (%) 2(6) —2(6) Neutropenia 0 0 Anemia 1(3) 1(3) Thrombocytopenia 13) 13) Grade 3/4 non-hematology toxicity regardless of relatedness 6(19) 0 Diarrhea 4(13) 0 Hyponatremia 216) 0 Enterocolitis hemorrhagic 1

  11. Slide 11: Median Percent Change From Baseline

    Median Percent Change From Baseline Treatment related lymphocytosis — ibrutinib affects microenvironment Transient surge in lymphocytes, less pronounced in TN2 65 yrs occurring with rapid resolution of lymph nodes 500 400) 200] 200) 100) 100! eens ALC=R/Rsingle agent — ALC~TNsingle agent sens SPD= R

  12. Slide 12: Response Criteria

    Response Criteria NHL IWG criteria’ were applied to SLL cases The 2008 IWCLL criteria? were applied to CLL cases with the following modifications: — Treatment-related lymphocytosis, in the absence of other parameters meeting the criteria for PD, was not considered PD in line with modified IWCLL (201

  13. Slide 13: Best Response

    Best Response 420 mg/d 840 mg/d Total (N=26) (N=5) (N=31) Median flu = 14.4 Median flu = 7.4 Median flu = 12.8 mos mos mos # (%) # (%) # (%) CR 3 (12) i) 3 (10) PR 18 (69) 2 (40) 20 (65) Nodal 3(12) 1 (20) 4 (13) sD 1(4) 1 (20) 2 (6) PD i) 0 0 NE 1(4) 1 (20) 2 (6) *Per IWCLL 2008 criteria

  14. Slide 14: PCYC-1102-CA: Best Response by Risk Features

    PCYC-1102-CA: Best Response by Risk Features (Treatment Naive 2 65 yrs) N ORR% (n) | CR% All Patients 31 74 (23) 10 (3) 270 years age 23 70 (16) 13 (3) Hgb < 11 g/dL or PLT < 100K/uL at 19 79 (15) 11 (2) screening IgVH unmutated 13 92 (12) 15 (2) Del17p present 2 100 (2) 0(0) 62 Microglobulin > 3mg/

  15. Slide 15: Sustained Improvement in Hemoglobin and platelet counts

    Sustained Improvement’ in Hemoglobin and platelet counts in patients with Pre- treatment Cytopenias Platelets 0% 10% 20% 30% 40% 50% 60% “Sustained improvement is defined as improvement in pretreatment cytopenia by >50%, or achieving a Hgb >11 g/dL OR pits >100,000 sustained for = 60 days without bl

  16. Slide 16: Response Rate %

    Response Rate % Cumulative Best Response— Treatment Naive 2 65 yrs 420 mg/d cohort (n=26)—Median f/u 14.4 months 90% 80% 73% ua 70% 60% a ai 9 50% x 50% 40% 46% EW 30% 27% 20% ry 7 10% | 0% Cycle 2 Cycle 5 : 8 11 m CR mPR_ gm Nodal Response 81% 69%) 12% Best Response 16

  17. Slide 17: Cumulative Best Response: Comparison of Relapsed/Refractory and Treatment Naive

    Cumulative Best Response: Comparison of Relapsed/Refractory (n=27) and Treatment Naive > 65 yrs (n=26) populations at 420 mg Faster Time HigherORR HigherCR cl to Response Rate 80% Ih 3S 70% pe 2 % 60% (4 50% ®% 50% 4% 8 40% 34% a 3 30% 27% = © ri 19% 46% 30% = J 0% TN RR ™N RR Cycle 2 Cycle 5 Weveie

  18. Slide 18: PFS Probability

    PFS Probability PCYC-1102-CA: Progression-free Survival (Treatment Naive 2 65 yrs) Estimated 15 mo PFS at 420mg/d = 96% 104 094 os4 07-4 064 os4 044 034 024 041-4 00-4 a ea oe eee ee — 420 mg/day — Naive (N=26) —— 840 mg/day — Naive (N=5) + Censored T (0) 2 4 6 8 10 12 14 16 18 20 Months on Study Da

  19. Slide 19: Summary

    Summary Ibrutinib administered as a single-agent to patients 265 years with treatment naive CLL: « Resulted in 81% of patients achieving an IWCLL response with estimated 15-month PFS of 96% with 420mg/d suggesting early durability of treatment benefit » Responses to the single agent include complete

  20. Slide 20: Acknowledgement

    Acknowledgement All the patients and their families who participated in the study Investigators and clinical research staff from all the clinical centers Pharmacyclics, Inc. Jamie-Sue West Anh Tran Zeena Salman Tasheda Navarro Sheila Lagura Stephen Chan Raymond Lee Julie Graves Clara Plascencia Joyc

Pharmacyclics — Technical Presentation (June 2012) on 6ix